An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers

Overview of attention for article published in Translational Neurodegeneration, May 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#41 of 387)
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news: 2 news outlets

twitter: 10 X users

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 13 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

An open-label multiyear study of sargramostim-treated Parkinson's disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers.

Alzforum, 26 May 2023

Olson KE, Abdelmoaty MM, Namminga KL, Lu Y, Obaro H, Santamaria P, Mosley RL, Gendelman HE.

Long-term sargramostim led to motor gains for 5 patients

PARKINSON'S NEWS TODAY, 26 May 2023

Long-term treatment with sargramostim, an immune-modulating medication from Partner Therapeutics, was safe and improved motor…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.